FDA sets strong warnings for asthma drug labels

	Tweet

The U.S. Food and Drug Administration said on Monday that product labels for three popular asthma medications have been updated to state that the drugs could increase the chance of severe asthma attacks that could result in death.

The warnings, first proposed last November, involve long-acting bronchodilator medicines Advair and Serevent, made by GlaxoSmithKline Plc, and Foradil from Novartis AG.

In a public health advisory issued on its Web site, the FDA said the inhaled drugs should only be used after other medicines, such as inhaled corticosteroids, fail to control asthma.

RELATED STORIES:
Pfizer Lipitor study has mixed results   US poll backs bigger gov’t role on drug prices   Senior FDA staff left out of contraceptive ruling   Pfizer arthritis drug gets heart test   FDA approves Atripla for the treatment of HIV-1 infection in adults   Injectable Osteoporosis Drug Shows Promise   Bayer starts selling quick-release aspirin   Clamor for obesity pill may test FDA limits   Roche says now shipping Tamiflu to all markets   Public to view drug side effects   Dutch court upholds Lipitor patent   Osteoporosis: Breaking Bones Is Big Business

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]